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In an ongoing survey for bioactive potential of microorganisms from different biosphere zones of India, a new
Chrysosporium lobatum strain BK-3 was isolated from soil sample collected from a biodiversity hotspot, Kaziranga
National Park, Assam, India. Bioactivity-guided purification resulted in the isolation of two bioactive compounds
whose chemical structures were elucidated by 1H and 13C Nuclear Magnetic Resonance (NMR), 2D-NMR, Fourier
Transform Infra-red (FT-IR) and mass spectroscopic techniques, and were identified as α, β-dehydrocurvularin and
curvularin. Only curvularin exhibited 80% acetylcholinesterase (AChE) inhibitory activity. Detailed ligand receptor
binding interactions were studied for curvularin by molecular docking studies. Further, both curvularin and α,
β-dehydrocurvularin had similar level of cytotoxicity against different human tumour cell lines like A549, HeLa,
MDA-MB-231 and MCF-7, while α, β-dehydrocurvularin was active against COLO 205 with a IC50 of 7.9 μM, but
curvularin was inactive. α, β-Dehydrocurvularin also showed good superoxide anion scavenging activity with an
EC50 value of 16.71 μg ml-1. Hence, both these compounds exhibited differences in bioactive profiles and this was
probably associated with their minor structural differences. This is a first report on bioactive compounds exhibiting
AChE inhibitory, cytotoxicity and antioxidant activities from Chrysosporium lobatum strain BK-3.
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dockingIntroduction
Alzheimer’s disease (AD), the most common neurode-
generative disorder associated with ageing, is accompan-
ied by severe deficiency in choline acetyltransferase
activity in the hippocampus and cerebral cortex. A sig-
nificant correlation has been found between the decrease
in cortical cholinergic activity and the deterioration of
mental test scores in patients suffering from AD. There-
fore, potentiation of central cholinergic activity has been
proposed as a possible therapeutic approach to improve
cognitive function in AD patients (Johnson et al. 2000).
Among the most promising strategies is the elevation of* Correspondence: cgkumar5@gmail.com
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in any medium, provided the original work is pthe brain concentration of the neurotransmitter acetyl-
choline by centrally acting acetylcholinesterase (AChE,
EC 3.1.1.7) inhibitors. During the past decade, several
cholinergic drugs have been launched in the market, in-
cluding the synthetic compounds like tacrine (Bartus et al.
1982), donepezil (E2020) (Watkins et al. 1994), galan-
thamine (Davis et al. 1995), and rivastigmine (Kawakami
et al. 1996). It has been reported that use of these drugs
produce significant cognitive improvement (Nightingale
1997; Kryger et al. 1999; McGleenon et al. 1999). However,
a major drawback in the widespread use of these synthetic
compounds as a general therapy is the appearance of un-
desirable side effects such as hepatotoxicity, which im-
poses severe dose-limits (Watkins et al. 1994).
The comprehensive study of the AChE/inhibitor com-
plexes by X-ray crystallography had indicated that AChEn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ing sites, an acylation site (active site) and a peripheral
site which was also called peripheral anionic site. Simul-
taneous binding to the catalytic anionic subsite and the
peripherical anionic site is responsible for the enhanced
binding of gorge-spanning ligands, such as galanthamine
and donepezil (E2020). Recent biochemical studies have
shown that the peripherical anionic site is also impli-
cated in promoting aggregation of the beta-amyloid (Aβ)
peptide responsible for the neurodegenerative process in
AD (Greenblatt et al. 1999; Tariot 2001; Bar-On et al.
2002). Thus, the design of inhibitors interacting with the
peripherical anionic site is of clear potential interest for
treatment of AD (Zeng et al. 1999).
Bioprospecting is a term coined recently to refer to the
search for novel products or microorganisms of economic
importance from the world’s biota. Over the past few years
a renewed interest has been generated on the investigation
of fungi as a potential source of novel bioactive com-
pounds like immunosuppressive, anti-cholesterolemic and
anti-tumour agents (Harvey 2000; Strobel 2000; Tulp and
Bohlin 2004). Most fungi investigated have been isolated
from soil samples and they have provided a broad spec-
trum of secondary metabolites with diverse chemical
structures; the most exciting recent discoveries have come
from exploration of fungi surviving in unusual ecological
niches like rain forests (Strobel 2000), marine sponges
(Höller et al. 2000), and mangroves (Lin et al. 2001). In
particular, AChE inhibitors were reported to be produced
by some soil fungi like arisugacin A and B from Penicillium
sp. FO 4259 (Kuno et al. 1996), quinolactacins A1 and A2
from Penicillium citrinum (Kim et al. 2001) and terreu-
lactones A, B, C and D from Aspergillus terreus (Kim et al.
2003). The present study reports on the isolation and
characterization of fungal acetylcholinesterase (AChE)
inhibitors from the hitherto unexplored biosphere, the
Kaziranga National Park, Assam, India. The Kaziranga Na-
tional Park (26° 30′ to 26° 45′N and 93° 05′ to 93° 40′E),
Assam, India is located on the southern bank of the
Brahmaputra river at the foot of the Mikir – Kirbi Anglang
Hills and is declared as a World Heritage site by UNESCO
in 1985. This park is one of the last areas in Eastern India
and is almost undisturbed by human and has a unique nat-
ural riverine landscape of sheer forest, tall elephant grass,
rugged reeds, marshes and shallow pools inhabited by the
world’s largest population of one-horned rhinoceroses and
diverse range of other wild animals (UNEP 2005; UNESCO
2010). Considering the importance of this hitherto unex-
plored biosphere, fungi were isolated from different soil
and dung samples collected from this forest and the meta-
bolic profiling of secondary metabolites produced by a
newly isolated Chrysosporium lobatum strain BK-3 was
carried out and assessed for their AChE inhibition, anti-
microbial, cytotoxicity and antioxidant activities.Materials and methods
Chemicals used
Acetylcholinesterase (AChE) from electric eel (EC
3.1.1.7); acetylthiocholine iodide (ATCI); 5,5′-dithiobis-
(2-nitrobenzoic acid) (DTNB); Trizma hydrochloride
(Tris–HCl) buffer solution, pH 8.0 and reference com-
pound like galanthamine hydrobromide from Lycoris
sp. were purchased from Sigma (St. Louis, MO, USA).
Fungal strain and fermentation conditions
The fungal strain BK-3 was isolated from a forest soil
sample collected from the Kaziranga National Park,
Assam, India, as part of a bioactives screening program
(Kumar et al. 2010). The pure culture was maintained in
the in-house culture repository of the institute with the
accession number ICTF-039 and based on the cultural
and morphological characteristics of spore and hyphae
by lactophenol blue staining and microscopic observa-
tion, the strain BK-3 was identified as Chrysosporium
lobatum. The strain BK-3 was pre-cultured aerobically at
30°C for 5 days in 1 L Erlenmeyer flasks containing
250 ml of potato dextrose broth medium and agitated at
150 rev min-1 in an orbital shaker for 120 h. The
fermented medium was later filtered through a muslin
cheese cloth to remove the fungal biomass and then the
infiltrate was centrifuged at 2000 rpm to obtain a cell-
free supernatant.
Extraction, analysis and purification of bioactive
metabolites
Bioactive compounds were extracted from the cell-free
supernatant by absorption onto Diaion HP-20 (3%, Supelco,
Bellafonte, PA, USA) resin. The resin was washed with
water and then extracted with methanol to obtain the crude
extract. The crude extract was analyzed by thin-layer chro-
matography (TLC) on silica gel 60 plates (F254, Merck).
Plates were developed in a methanol-chloroform (5:95)
solvent mixture and visualized under UV light at
254 nm which revealed the presence of two bioactive
compounds. The extracted compound was further con-
centrated under reduced pressure on a rotary vacuum
evaporator (Rotavapor R-205, Büchi, Switzerland) and
further profiled on silica gel (60–120 mesh) column
(3 × 60 cm) with methanol-chloroform solvent system
as a mobile phase. Spot 1 was eluted in methanol-
chloroform mixture (1:99, v/v). The same solvent mix-
ture was continued till compound 1 was completely eluted
and after drying gave a pale yellow powder. Spot 2 was
eluted in methanol-chloroform mixture (1.5:98.5, v/v), and
drying of the fractions resulted in compound 2 as white
powder. Both compounds were UV-active and visualized
under UV light at 254 nm, as well as by spraying with
phosphomolybdic acid followed by heating at 100°C for
2–3 min which appeared as blue coloured spots.
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The purified compounds were further subjected to 1H and
13C NMR, FT-IR, ESI-MS along with 2D-NMR spectro-
scopic studies like HMBC, HSQC, 1H-1H-COSY, NOSEY
and DEPT-135 studies for elucidating their structures. The
UV and visible spectra were measured by dissolving the
samples in spectroscopic acetonitrile and recorded at 30°C
on a UV-visible double beam spectrophotometer (Lambda
25, Perkin-Elmer, Shelton, CT). Nuclear magnetic reson-
ance (NMR) spectra were recorded on a Bruker Avance
300 MHz NMR spectrometer (Bruker, Switzerland). The
1H and 13C NMR spectra were determined in deuterated
chloroform at room temperature, and chemical shifts
were represented in δ values (ppm) with tetramethylsilane
(TMS) as an internal standard. The Fourier transform in-
frared spectrum (FT-IR) was performed using the Thermo-
Nicolet Nexus 670 FT-IR spectrophotometer (Thermo
Fisher Scientific Inc., Madison, WI, USA) using KBr pellets
and spectra were collected at a resolution of 4 cm-1 in the
wavenumber region of 400–4,000 cm-1. The high reso-
lution mass spectra (HR-MS) were recorded on a QSTAR
XL Hybrid ESI-Q TOF mass spectrometer (Applied
Biosystems Inc., Fosters City, CA, USA). Electrothermal
Digital 9000 Series melting point apparatus (Model
IA9200, Barnstead, UK) was used for determining the
melting point of the purified compounds. The purified
sample (1 mg) of each bioactive compound was placed in a
glass capillary tube and this tube was placed in an alumin-
ium heating block which was heated at a fast ramp rate of
10°C min-1 from a temperature range of 25 to 300°C for
melting point measurement.
Antimicrobial activity
Antimicrobial activity was determined using the broth di-
lution method as described previously (Kumar and
Mamidyala 2011). The target strains used for screening the
antimicrobial activities were Micrococcus luteus MTCC
2470, Staphylococcus aureus MTCC 96, Staphylococcus
aureus MLS16 MTCC 2940, Bacillus subtilis MTCC 121,
Escherichia coli MTCC 739, Pseudomonas aeruginosa
MTCC 2453, Klebsiella planticola MTCC 530 and Can-
dida albicans MTCC 3017. These strains were procured
from Microbial Type Culture Collection and Gene Bank
(CSIR-Institute of Microbial Technology, Chandigarh,
India).
In vitro cytotoxicity testing
Cytotoxicity of the compounds was assessed on the basis
of the measurement of the in vitro growth in the 96 well
plates by cell-mediated reduction of tetrazolium salt to
water insoluble formazan crystals by a previously de-
scribed method (Mosmann 1983). Cell lines for testing
in vitro cytotoxicity included HeLa derived from human
cervical cancer cells (ATCC No. CCL-2), A549 derivedfrom human alveolar adenocarcinoma epithelial cells
(ATCC No. CCL-185), MDA-MB-231 derived from hu-
man breast adenocarcinoma cells (ATCC No. HTB-26),
MCF7 derived from human breast adenocarcinoma cells
(ATCC No. HTB-22), COLO 205 derived from human
colon cancer cell line (ATCC No CCL-222), K562 de-
rived from human chronic myelogenous leukemia cell
line (ATCC No. CCL-243) and HEK 293 derived from
human embryonic kidney cell line (ATCC No. CRL-1573)
were obtained from American Type Culture Collection,
Manassas, VA, USA. The IC50 values (50% inhibitory
concentration) were calculated from the plotted absorb-
ance data for the dose–response curves. The IC50 values
(in μM) were expressed as the average of two independ-
ent experiments.
Antioxidant activities
The purified compounds were investigated for their anti-
oxidant potentials in different oxidizing systems, viz., rad-
ical scavenging activity by 1,1-diphenyl-2-picrylhydrazyl
(DPPH) reduction (Kumar et al. 2011), superoxide radical
scavenging activity (Liu et al. 1997), inhibition of lipid per-
oxidation (Zhang and Yu 1997) and hemolysis in erythro-
cyte membrane stabilization (Ng et al. 2000) at different
concentrations. Ascorbic acid and luteolin were also
employed as standards in these assays. All experiments
were carried out in triplicates and the EC50 (50% effective
concentration) values (μg ml-1) were expressed as the
mean ± standard deviation (S.D.).
In vitro acetylcholinesterase (AChE) assay
AChE inhibitory activity for the purified compounds was
performed using the modified method of Ellman et al
(1961) in 96 well plates (Rhee et al. 2001). The concen-
tration of the compound that inhibited 50% of AChE ac-
tivity (IC50) was estimated by plotting percent activity
and percent inhibition of AChE versus inhibitor concen-
trations on the same graph. The concentration at the
intersection of these two curves was the IC50 value.
Protein–ligand docking studies
The molecular docking studies were performed using vari-
ous docking softwares like GOLD (Genetic Optimization
for Ligand Docking, version 3.2) and CDOCKER (in Dis-
covery Studio 2.5) on the curvularin molecule with the
well-known complex acetylcholinesterase complexed with
E2020 which is marketed as Aricept (PDBID: 1EVE)
(Badrinarayan et al. 2011). The Accelrys Discovery studio
protein preparation wizard was used to prepare the pro-
tein with default settings. The ligands were subjected to
energy minimization at AM1 level of theory. The default
parameters in GOLD 3.2 such as number of islands 5,
population size of 100, number of operations was 100,000,
a niche size of 2, a selection pressure of 1, the van der
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spectively, have been used to perform GOLD docking
calculations (Srivani et al. 2007; Ravindra et al. 2008;
Badrinarayan and Sastry 2011). The CDOCKER had an
all-atom CHARMm force field-based docking algorithm
and used the soft-core potentials with an optional grid
representation to dock ligands into the active site of the
receptor. CDOCKER generated the random ligand con-
formations through molecular dynamics simulation.
CDOCKER docking was done with the default parame-
ters using the ligand E2020 as the center.
Results
Purification, characterization and structure elucidation of
bioactive compounds
The culture filtrate of strain BK-3 revealed the presence of
two major spots in TLC with Rf values of 0.5 for com-
pound 1 and 0.3 for compound 2 which were separated
in a solvent mixture of methanol:chloroform solvent sys-
tem. Compound 1: Yield: 50 mg l-1; pale yellow powder;
heat stable and showed no change in its activity, when
autoclaved at 121°C for 30 min; mp 218–220°C. UV λmax
(EtOH) (loge): 225 (4.247).
1H-NMR (DMSO-d6 500 MHz)
δ (ppm): 1.11 (3H, d, J = 6.42, 4-CH3), 1.46 (1H, m, H-6),
1.48 (1H, m, H-5), 1.75 (1H, m, H-5), 1.82 (1H, m, H-6),
2.19 (1H, m, H-7), 2.28 (1H, m, H-7), 3.36 (1H, d, J = 15.57,
H-1), 3.39 (1H, d, J = 15.57, H-1), 4.74 (1H, m, H-4), 6.23
(2H, s, H-12, H-14), 6.3 (1H, d, J = 15.74, H-9), 6.38 (1H,
m, H-8). 13C-NMR (DMSO-d6 500 MHz) δ (ppm): 20.11
(q, 4-CH3), 23.94 (t, C-6), 32.9 (t, C- 7), 33.53 (t, C-5),
39.94 (t, C-1), 72.28 (d, C-4), 101.62 (d, C-12), 109.71 (d,
C-14), 118.18 (s, C-16), 132.72 (d, C-9), 133.95 (s, C-15),
153.75 (d, C-8), 157.62 (s, C-13), 159.25 (s, C-11), 170.43
(s, C-2), 197.75 (s, C-10). IR (KBr) (νmax cm
-1): 3470 and
3300 (hydroxyl), 1720 (lactone), 1600 (conjugated aromatic
system), 1300 and 970 (conjugated trans-CH =CH-), 843
(1,2,3,5-tetrasubstituted benzene). MS (ESI) m/z: 291.1 [M
+H]+; HR-MS (ESI) m/z calculated for C16H18O5 [M+H]
+:
290.32, found: 291.122. Based on the spectral data
(Additional file 1: Figure S1-S7) and its comparison withO
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(a) α, β-Dehydrocurvularin 
Figure 1 Structures for (a) α, β-dehydrocurvularin and (b) curvularin pthat of the authentic data from the reported literature
(Munro et al. 1976; Arai et al. 1989; Jiang et al. 2008), the
compound 1 was identified as α, β-dehydrocurvularin
(Figure 1).
Compound 2: Yield: 60 mg l-1; white powder (MeOH),
mp 205–208°C. UV λmax (EtOH) (loge): 225 (4.247). MF:
C16H20O5;
1H NMR (CDCl3, 300 MHz) δ (ppm): 9.49
(1 H, s, 16-OH), 9.26(1 H, s, 14-OH), 6.38 (1 H, s, H-15),
6.15 (1 H, d, H-13), 4.87 (1 H, m, H-8), 3.64 (2 H, s, H-11),
2.77 (1 H, m, H-3a), 2.56 (1 H, d, m, H-3b), 1.77-1.18
(8 H, m, H-4,5,6,7), 1.14 (3 H, d, 8-CH3).13C NMR data
(CDCl3, 300 MHz) δ (ppm): 206.05 (C-2), 170.19 (C-10),
159.13 (C-16), 157.28 (C-14), 135.28 (C-12), 119.62 (C-1),
110.92 (C-13), 101.59 (C-15), 71.42 (C-8), 42.89 (C-3),
40.33 (C-11), 31.56 (C-7), 26.18 (C-5), 23.28 (C-6), 22.26
(C-4), 20.08 (8-CH3). IR (KBr): 3425 (br), 2924, 1722,
1609, 1592, 1264. MS (ESI) m/z: 293 [M+H]+; HR-MS
(ESI) m/z calculated for C16H20O5 [M+H]
+: 292.33, found:
292.11. The spectral data of the compound 2 (Additional
file 1: Figure S8; Additional file 1: Figure S9; Additional file
1: Figure S10; Additional file 1: Figure S11; Additional file
1: Figure S12; Additional file 1: Figure S13;Additional file 1:
Figure S14; Additional file 1: Figure S15; Additional file 1:
Figure S16) were identical with that of the authentic data
from the reported literature (Musgrave 1957; Ghisalberti
et al. 1993) and was identified as curvularin (Figure 1).
Acetylcholine esterase inhibitory activity
The initial crude extract showed 60% of AChE inhibi-
tory activity. Among the two purified compounds,
only curvularin exhibited positive AChE inhibitory ac-
tivity showing 80% inhibition as compared to standard
galanthamine which showed 75% inhibition. The IC50
values determined for curvularin and galanthamine
(standard) were 1.36 and 2.625 μM ml-1.
Antimicrobial susceptibility testing and cytotoxicity
Antimicrobial susceptibility tests of the purified metabo-
lites profiled from strain BK-3 indicated that both the com-
pounds did not exhibit any antimicrobial activity against allO
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O
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roduced by Chrysosporium lobatum strain BK-3.
Table 1 In vitro cytotoxicity of bioactive compounds produced by Chrysosporium lobatum strain BK-3
Compounds IC50 values (μM) (Mean ± S.D.
b)
MCF-7 A549 MDA-MB-231 COLO 205 K562 HeLa HEK293 (normal)
α, β-Dehydrocurvularin 11.19 ± 0.31 2.10 ± 0.33 9.34 ± 0.38 7.9 ± 0.09 –a 21.01 ± 0.19 –
Curvularin 21.89 ± 0.19 13.91 ± 0.15 1.3 ± 0.37 – – 25.64 ± 0.37 –
Doxorubicin (Standard) 1.05 ± 0.37 1.21 ± 0.41 0.501 ± 0.26 0.985 ± 0.33 0.318 ± 0.26 0.451 ± 0.25 –
a– No activity; bS.D.: Standard deviation.
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dida albicans. Further, the in vitro cytotoxicity evaluated
against a panel of human tumor cell lines (Table 1), indi-
cated that both curvularin and α, β-dehydrocurvularin had
similar level of anti-tumour activity against A549, HeLa,
MDA-MB-231 and MCF-7, while α, β-dehydrocurvularin
was active against COLO 205 with an IC50 of 7.9 μM; how-
ever, curvularin was inactive.
Antioxidant activities
The EC50 (μg ml
-1) values of the total DPPH scavenging,
superoxide anion scavenging, lipid peroxidation inhibition,
erythrocyte hemolytic inhibition activities of curvularin,
α, β-dehydrocurvularin, ascorbic acid and luteolin (as
standards) is shown in Table 2. α, β-Dehydrocurvularin
showed significant antioxidant potential, however, curvu-
larin did not exhibit any antioxidant activity.
Molecular docking studies
The molecular docking studies were carried out to evalu-
ate the binding affinity of curvularin and the reversible
cholinesterase inhibitor galanthamine with acetyl cholin-
esterase (AChE) enzyme using GOLD (version 3.2) and
CDOCKER (Discovery Studio version 2.5) docking soft-
wares. These studies were performed on curvularin and
galanthamine with well-known enzyme acetylcholinester-
ase complexed with E2020 which is marketed as Aricept
(PDBID: 1EVE) (Kryger et al. 1999). The active site radius
was set to 10 Å, which formed the atom number 1284,
and the nitrogen atom of the active site residue Trp84,
which formed π–π interactions with E2020. The default
parameters had been used for the docking studies in the
above mentioned docking softwares. The GOLD docking
results showed good activity with 49.736 and 52.06
docking scores, CDOCKER showed 53.93 and 37.72Table 2 Antioxidant properties of bioactive compounds prod
Assays
α, β–Dehydrocurvularin
DPPH scavenging activity 50.75 ± 0.14
Superoxide anion scavenging activity 16.71 ± 0.16
Lipid peroxidation inhibition 159.09 ± 0.09
Erythrocyte hemolytic inhibition 141.79 ± 0.21
a– No activity; bS.D.: Standard deviation.docking scores for curvalarin and galanthamine, respect-
ively (Table 3). The interactions of ligands in the binding
site have been depicted in Figure 2.
The compound curvularin exhibited strong hydrogen
bonding interactions (CH-O and OH-O) with ASP72,
GLY119 and PHE331 residues. The N-H of the HIS440
residue showed a strong hydrogen bonding interaction
with oxygen of the hydroxyl group presented in the
curvularin. The ligand formed OH-O type of hydrogen
bonding interactions with hydroxyl groups of tyrosine
residues TYR334, 70 and 121 in the active site. The
PHE330, 331 and TYR334 residues formed hydrophobic
interactions with the curvularin ligand. All the above
mentioned interactions were in the range of less than
4.00 Å between ligand and binding site residues. The
curvularin showed similar interactions as Aricept ligand,
the bottom of the binding site showed a strong inter-
action on one face of the benzyl ring and displayed a
classic π–π stacking with the six-membered ring of
TRP84 indole. At the middle of the binding site
curvularin showed an interaction with PHE330 and
TYR121 residues in the hydrophobic fashion. On other
hand this ligand also formed a strong hydrogen bond
interaction with HIS440 residue. The docking results of
curvularin molecule were compared with the existing drug
galanthamine to compare the various parameters such as
score and different type of interactions. Galanthamine
showed strong hydrogen bonding interactions with
ASP72, GLY118 and TYR121 residues similar to curvu-
larin, however, the strong hydrogen bonding interactions
with HIS440 and GLY119 residues which was absent in
galanthamine. The galanthamine showed another import-
ant hydrophobic interaction with PHE331 and TYR334
which is similar to curvularin interactions in the middle of
the binding site. The above analysis clearly shows thatuced by Chrysosporium lobatum strain BK-3
EC50 (μg ml
-1) (Mean ± S.D.b)
Curvularin Ascorbic acid (Standard) Luteolin (Standard)
–a 40.28 ± 0.27 44.18 ± 0.15
– 21.01 ± 0.36 31.01 ± 0.11
– 139.97 ± 0.30 134.1 ± 0.19
– 119.81 ± 0.30 122.00 ± 0.10
Table 3 Docking results of curvularin produced by
Chrysosporium lobatum strain BK-3 with acetyl
cholinesterase enzyme (PDBID: 1EVE) using various
docking protocols
Structure Different docking protocols
GOLD CDOCKER
Curvularin 44.40 53.93
Galanthamine 52.06 37.72
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the existing drug galanthamine in the active site.
Discussion
AChE inhibitors have therapeutic applications in AD, se-
nile dementia, ataxia, myasthenia gravis and Parkinson’s
disease (McGleenon et al. 1999). Global interests in nat-
ural products have increased of late due to safety con-
cerns of synthetic products. All of the known AChE
inhibiting drugs used in the clinics suffer from several
side effects such as high toxicity, short duration ofFigure 2 The typical residue interactions of curvularin and galantham
1EVE) using (a) GOLD and (b) CDOCKER docking protocols.biological action, low bioavailability and narrow thera-
peutic effects (Lee et al. 2011). Consequently, there is a
need for the development of new AChE inhibitors with
less toxicity and more potency. Only three fungal species
like Penicillium sp. (Kuno et al. 1996; Kim et al. 2001),
Aspergillus terreus (Kim et al. 2003), and Sporothrix sp.
(Wen et al. 2009) have been reported so far to produce
compounds with AChE inhibitory activity. In the present
study, we report the bioassay-guided purification of α,
β-dehydrocurvularin and curvularin (Figure 1) from
Chrysosporium lobatum strain BK-3 and their structure elu-
cidation. Based on the AChE inhibition and cytotoxicity
screen-ing assays, we found that curvularin and α, β-
dehydrocurvularin have slightly different bioactivity profiles.
α, β-Dehydrocurvularin and curvularin and their derivatives
were earlier reported to be produced by some fungi such as
Aspergillus aureofulgens (Caputo and Viola 1977),
Alternaria cinerariae (Arai et al. 1989), Curvularia
eragrostidis (Bicalho et al. 2003), Penicillium sp. (Zhan et al.
2004), Nectria galligena (Gutierrez et al. 2005) and
Eupenicillium sp. (Xie et al. 2009). Curvularin is aine in the active site of acetylcholinesterase enzyme (PDBID:
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and acted as a non-specific phytotoxin (Robeson and
Strobel 1981). Other activities reported for curvularin and
its derivatives are as potential nematicides against the root-
lesion nematode, Pratylenchus penetrans (Kusano et al.
2003) and as a bioherbicide (Jiang et al. 2008). More inter-
estingly, these derivatives were identified as cell division in-
hibitors (Ghisalberti et al. 1993), specifically disordering the
microtubule centers (Almassi et al. 1994) and inducing
barrel-shaped spindles (Kobayashi et al. 1988).
The anti-tumour activity of curvularin was not re-
ported earlier and the IC50 values were assayed accor-
ding to the MTT method. The results showed that
both curvularin and α, β-dehydrocurvularin were active
against the tumour cell lines. The IC50 values of α,
β-dehydrocurvularin were almost always one order of
magnitude higher than those of curvularin against the
corresponding test cell lines except for MDA-MB-231
cell line, which might be due to the lack of the
3,4-double bond (unsaturation) in curvularin. Based on
their chemical structures (Figure 1), there is only one
functional group difference between the two com-
pounds; α, β-dehydrocurvularin has a double bond be-
tween C-3 and C-4 position, while curvularin has none
in the corresponding position. In case of flavonoid-type
compounds, the structure-activity relationship (SAR)
was explained by the fact that the presence of a double
bond is the only structural difference between two
flavonoids (as one counterpart), which is one of the im-
portant structural property essential for effective inter-
action between flavonoid and the breast cancer
resistance protein, and the flavonoid compound with
double bond is more active than its counterpart (Zhang
et al. 2005). It was earlier reported that the bioactivity
of some other class of chemical compounds with
double bond was notably stronger than those of their
corresponding hydrogenated derivatives (Dizhbite et al.
2004; González-Díaz et al. 2007; Cheng et al. 2008).
In one report (Gutierrez et al. 2005), it was indicated that
α, β-dehydrocurvularin produced by Nectria galligena
showed no IC50 value reported for α, β-dehydrocurvularin
even at the use concentration of >300 μm. Further, the α,
β-dehydrocurvularin exhibited cytotoxic activity with IC50
value of <12 μg ml-1 against human lung fibroblast cell
line (MRC-5), while the α, β-dehydrocurvularin pro-
duced by Chrysosporium lobatum strain BK-3 showed
cytotoxic activity with IC50 values of 2.10 μM against
A549, 7.9 μM against COLO-205 and 9.34 μM against
MDA-MB-231. From these results, it clears that α,
β-dehydrocurvularin from Nectria galligena exhibited only
cytotoxic activity but no AChE inhibitory activity. Further,
α, β-dehydrocurvularin from Nectria galligena exhi-
bited antimicrobial activity only against Pseudomonas
syringae with IC350 value of 14.2 μg ml
-1, while α,β-dehydrocurvularin from Chrysosporium lobatum did
not exhibit any antimicrobial activity against the tested
microbial strains.
Conclusions
This study demonstrated that curvularin and α, β-
dehydrocurvularin were the two main structurally related
secondary metabolites produced by Chrysosporium loba-
tum strain BK-3 with slightly different bioactive profiles.
Both these compounds were active against different cancer
cell lines. However, α, β-dehydrocurvularin did not exhibit
inhibition for AChE, while curvularin did, which suggested
that the partial planar backbone structure in the presence
of a 3,4-double bond played an important role in the in-
hibition of AChE activity. Further, the docking analysis
showed that similar to Aricept ligand, curvularin showed a
strong hydrogen bonding and hydrophobic interactions in
the bottom and middle of the binding site of AChE en-
zyme. Curvularin had good docking scores as compared
to the existing drug galanthamine; in case of CDOCKER
curvularin had higher docking score than galanthamine
(53.931 and 37.72, respectively). The docking study clearly
revealed that the curvularin molecule had better interac-
tions and it was fitting very well into the receptor of AChE
enzyme. It was showing better interactions than
galanthamine. To the best of our knowledge this is a first
study on the characterization of metabolites of
Chrysosporium lobatum strain BK-3 isolated from
Kaziranga National Park biosphere exhibiting AChE in-
hibitory, cytotoxicity and antioxidant activities.
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